Oral GLP-1s: what’s real, what’s pipeline, what’s marketing

The approved options

Rybelsus: oral semaglutide, T2D indication, established but lower-dose than injectable weight-loss regimens. Oral Wegovy: the 2025 weight-management pill — same molecule as the injection with absorption engineering (and 30-minute fasting rules) doing the heavy lifting; miss the rules and you’re under-dosed. Availability through NovoCare and covered channels; the brand list tracks cash routes as they’re recorded.

The pipeline, dated

Orforglipron is the one to watch: small-molecule (not peptide), daily, no food restrictions, phase-3 weight-loss results in the mid-to-high single digits through ≈10%+ depending on dose and trial — with regulatory submission progressing as of our recording. CagriSema (cagrilintide + semaglutide, injectable) posted ≈20%+ results and sits at the approval frontier. Neither is a thing you can lawfully buy today from a telehealth menu — any site claiming otherwise fails the legitimacy checklist instantly.

Compounded tablets, sublingual drops, gummies

The honest physics: semaglutide is a peptide the gut destroys; the approved oral products exist because of specific absorption technology. Compounded sublingual tablets and drops publish no equivalent absorption evidence — our tablets deep-dive walks the data gap. Gummies, gum, and lozenges marketed as “GLP-1” are supplements wearing a drug costume — no GLP-1 agonist, no evidence, skip. If needle-free is the requirement, the approved pills are the evidence-backed route; if budget is the requirement, injectable compounded remains the price floor.